Statin use and the risk of gallstone disease: a population-based case–control study

Bibliography

• Shaffer EA. Gallstone disease: epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol 2006;20:981-96
   PubMed Web of Science ®Google Scholar
• Sandler RS, Everhart JE, Donowitz M, The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500-11
   PubMed Web of Science ®Google Scholar
• Jorgensen T. Abdominal symptoms and gallstone disease: an epidemiologic investigation. Hepatology 1989;9:856-60
   PubMed Web of Science ®Google Scholar
• Portincasa P, Moschetta A, Petruzzelli M, Gallstone disease: symptoms and diagnosis of gallbladder stones. Best Pract Res Clin Gastroenterol 2006;20:1017-29
   PubMed Web of Science ®Google Scholar
• Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet 2006;368:230-9
   PubMed Web of Science ®Google Scholar
• Lammert F, Miquel JF. Gallstone disease: from genes to evidence-based therapy. J Hepatol 2008;48(Suppl 1):S124-35
   PubMed Web of Science ®Google Scholar
• Ciaula AD, Wang QH, Wang HH, Targets for current pharmacological therapy in cholesterol gallstone disease. Gastroenterol Clin North Am 2011;39:245-66
   Web of Science ®Google Scholar
• Wong WW, Dimitroulakos J, Minden MD, HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002;16:508-19
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Hebert PR, Gaziano JM, Chan KS, Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997;278:313-21
   PubMed Web of Science ®Google Scholar
• Kallien G, Lange K, Stange EF, The pravastatin-induced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans. Hepatology 1999;30:14-20
   PubMed Web of Science ®Google Scholar
• Abedin MZ, Narins SC, Park EH, Lovastatin alters biliary lipid composition and dissolves gallstones: a long-term study in prairie dogs. Dig Dis Sci 2002;47:2192-210
   PubMed Web of Science ®Google Scholar
• Saunders KD, Cates JA, Abedin MZ, Lovastatin inhibits gallstone formation n the cholesterol-fed prairie dog. Ann Surg 1991;214:149-54
   PubMed Web of Science ®Google Scholar
• Davis KG, Wertin TM, Schriver JP. The use of simvastatin for the prevention of gallstones in the lithogenic prairie dog model. Obes Surg 2003;13:865-8
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tuzcu EM, Sipahi I, Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007;297:499-508
   PubMed Web of Science ®Google Scholar
• Rogers SL, Magliano DJ, Levison DB, A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. Clin Ther 2007;29:242-52
   PubMed Web of Science ®Google Scholar
• Tsai CJ, Leitzmann MF, Willett WC, Statin use and the risk of cholecystectomy. Gastroenterology 2009;136:1593-600
   PubMed Web of Science ®Google Scholar
• Bodmer M, Brauchli YB, Krahenbuhl S, Statin use and risk of gallstone disease followed by cholecystectomy. JAMA 2009;302:2001-7
   PubMed Web of Science ®Google Scholar
• Merzon E, Weiss NS, Lustman AJ, Statin administration and risk of cholecystectomy: a population-based case-control study. Expert Opin Drug Saf 2010;9:539-43
   PubMed Web of Science ®Google Scholar
• Erichsen R, Froslev T, Lash TL, Long-term statin use and the risk of gallstone disease: a population-based case-control study. Am J Epidemiol 2011;173:162-70
   PubMed Web of Science ®Google Scholar
• Caroli-Bosc FX, Le Gall P, Pugliese P, Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci 2001;46:540-4
   PubMed Web of Science ®Google Scholar
• Gonzalez-Perez A, Garcia-Rodriguez LA. Gallbladder disease in the general population: association with cardiovascular morbidity and therapy. Pharmacoepidemiol Drug Saf 2007;16:524-31
   PubMed Web of Science ®Google Scholar
• Chiu HF, Ho SC, Chen CC, Statin use and the risk of liver cancer: a population-based case-control study. Am J Gastroenterol 2011;106:894-8
   PubMed Web of Science ®Google Scholar
• Kuo HW, Tsai SS, Tiao MM, Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf 2010;19:745-51
   PubMed Web of Science ®Google Scholar
• Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology 2007;18:213-19
   PubMed Web of Science ®Google Scholar
• Coogan PF, Rosenberg L, Palmer JR, Statin use and the risk of breast and prostate cancer. Epidemiology 2002;13:262-7
   PubMed Web of Science ®Google Scholar
• Meier CR, Scheinger RG, Kraenzlin ME, HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3205-10
   PubMed Web of Science ®Google Scholar
• Wang PS, Solomon DH, Mogun H, HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3211-16
   PubMed Web of Science ®Google Scholar
• Rejnmark L, Plsen ML, Johnsen SP, Hip fracture risk in statin users - a population-based Danish case-control study. Osteoporos Int 2004;15:452-8
   PubMed Web of Science ®Google Scholar
• Jadhav SB, Jain GK. Statins and osteoporosis: new role for old drugs. J Pharm Pharmacol 2006;58:3-18
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Center for Drugs Statistics Methodology. ATC Index with DDDs 2003. WHO, Oslo; 2003
   Google Scholar
• Hanson DS, Duane WC. Effects of lovastatin and chenodiol on bile acid synthesis, bile lipid composition, and biliary lipid secretion in healthy human subjects. J Lipid Res 1994;35:1462-8
   PubMed Web of Science ®Google Scholar
• Loria P, Bertolotti M, Cassinadri MT, Short-term effects of simvastatin on bile acid synthesis and bile lipid secretion in human subjects. Hepatology 1994;19:882-8
   PubMed Web of Science ®Google Scholar
• Tazuma S, Hatsushika S, Aihara N, Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs. Digestion 1992;51:179-84
   PubMed Web of Science ®Google Scholar
• Smith JW, van Erpecum KJ, Renooij W, The effects of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease. Hepatology 1995;21:1523-9
   PubMed Web of Science ®Google Scholar
• Duane WC, Hunninghake DB, Freeman ML, Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology 1988;8:1147-50
   PubMed Web of Science ®Google Scholar
• Reihner E, Rudling M, Stahlberg D, Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med 1990;323:224-8
   PubMed Web of Science ®Google Scholar
• Smith JW, van Erpecum KJ, Portincasa P, Effects of Simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia. Gut 1995;37:654-9
   PubMed Web of Science ®Google Scholar
• . Sharma BC, Agarwal DK, Baijal SS, Saraswat VA. Pravastatin has no effect on bile lipid composition, nucleation time, and gallbladder motility in persons with normal levels of cholesterol. J Clin Gastroenterol 1997;25:433-6
   PubMed Web of Science ®Google Scholar
• Chapman BA, Burt MJ, Chisholm RJ, Dissolution of gallstones with simvastatin, an HMG-CoA reductase inhibitor. Dig Dis Sci 1998;43:349-53
   PubMed Web of Science ®Google Scholar
• Porsch-Ozcurumez M, Hardt PD, Schnell-Kretschmer H, Effects of fluvastatin on biliary lipids in subjects with an elevated cholesterol saturation index. Eur J Clin Pharmacol 2001;56:873-9
   PubMed Web of Science ®Google Scholar
• Smith JL, Roach PD, Wittenberg LN, Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. J Gastroenterol Hepatol 2000;15:871-9
   PubMed Web of Science ®Google Scholar
• Miettinen TE, Kiviluoto T, Taavitsainen M, Cholesterol metabolism and serum and biliary noncholesterol sterols in gallstone patients during simvastatin and ursodeoxycholic acid treatments. Hepatology 1998;27:649-55
   PubMed Web of Science ®Google Scholar
• Akriviadis EA, Hatzigavriel M, Kapnias D, Treatment of biliary colic with diclofenac: a randomized double-blind, placebo-controlled study. Gastroenterology 1997;113:225-31
   PubMed Web of Science ®Google Scholar
• Goldman G, Kahn PJ, Alon R, Biliary colic treatment and acute cholecystitis prevention by prostaglandin inhibitor. Dig Dis Sci 1989;34:809-11
   PubMed Web of Science ®Google Scholar
• Leitzmann MF, Willett WC, Rimm EB, A prospective study of coffee consumption and the risk of symptomatic gallstone disease in men. JAMA 1999;281:2106-12.
   PubMed Web of Science ®Google Scholar